Patents by Inventor Tetsuya Gatanaga
Tetsuya Gatanaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8101174Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: GrantFiled: October 29, 2007Date of Patent: January 24, 2012Assignee: The Regents of The University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Patent number: 7807387Abstract: This disclosure describes inventions related to the use of biological agents that cause cytokine receptors to be released from the surface of cells. One aspect of this invention is based on the unexpected finding that extending the length of an exemplary agent at the N-terminus enhances expression and production of the product by at least 10-fold. The extended protein can be used to prepare pharmaceutical compositions for treating inflammatory conditions such as rheumatoid arthritis. Another aspect of this invention is based on the identification of biological agents that cause release of cytokine receptors not previously known as natural enzyme targets, such as the IL-1 Type I receptor, IL-1 Type II receptor and the IL-6 receptor. This disclosure provides products, assays, expression systems, purification methods, and production protocols useful for developing cytokine receptor releasing proteins as therapeutic agents.Type: GrantFiled: March 23, 2006Date of Patent: October 5, 2010Assignee: Meyer Pharmaceuticals LLCInventors: Tetsuya Gatanaga, Ronald L. Niece, Sheldon Broedel
-
Patent number: 7399465Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: GrantFiled: October 15, 2004Date of Patent: July 15, 2008Assignee: The Regents of the University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Publication number: 20080160002Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: ApplicationFiled: October 29, 2007Publication date: July 3, 2008Inventors: Tetsuya Gatanaga, Gale A. Granger
-
Publication number: 20080102075Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: ApplicationFiled: October 29, 2007Publication date: May 1, 2008Inventors: Tetsuya Gatanaga, Gale Granger
-
Publication number: 20070149453Abstract: This disclosure describes inventions related to the use of biological agents that cause cytokine receptors to be released from the surface of cells. One aspect of this invention is based on the unexpected finding that extending the length of an exemplary agent at the N-terminus enhances expression and production of the product by at least 10-fold. The extended protein can be used to prepare pharmaceutical compositions for treating inflammatory conditions such as rheumatoid arthritis. Another aspect of this invention is based on the identification of biological agents that cause release of cytokine receptors not previously known as natural enzyme targets, such as the IL-1 Type I receptor, IL-1 Type II receptor and the IL-6 receptor. This disclosure provides products, assays, expression systems, purification methods, and production protocols useful for developing cytokine receptor releasing proteins as therapeutic agents.Type: ApplicationFiled: March 23, 2006Publication date: June 28, 2007Inventors: Tetsuya Gatanaga, Ronald Niece, Sheldon Broedel
-
Publication number: 20070148130Abstract: This disclosure provides a new family of proteins implicated in causing the release of TNF receptors and other cytokine receptors from the surface of cells involved in inflammation. Receptor releasing activity was isolated and purified from a monocyte cell line, and sequenced to deduce the gene and protein structure of several different metalloproteases. The information provided in this disclosure enables the user to prepare recombinant protein or expression vectors that will cause receptor release in vivo, thus preventing signal transduction and blocking the effect of incoming cytokines. Medicaments containing cytokine receptor releasing activity are described for use in treating rheumatoid arthritis and other conditions mediated by inflammatory cytokines. The proteins of this invention are all relatively small single-chain molecules, and are therefore easier to use and more cost-effective than other currently marketed biological anti-inflammatory agents.Type: ApplicationFiled: November 1, 2006Publication date: June 28, 2007Inventors: Tetsuya Gatanaga, Michael Medrano, Ronald Niece
-
Patent number: 6955894Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: GrantFiled: May 14, 1999Date of Patent: October 18, 2005Assignee: The Regents of the University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Publication number: 20050191661Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: ApplicationFiled: December 13, 2004Publication date: September 1, 2005Inventors: Tetsuya Gatanaga, Gale Granger
-
Patent number: 6930084Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: GrantFiled: November 13, 2000Date of Patent: August 16, 2005Assignee: The Regents of the University of CaliforniaInventors: Gale A. Granger, Tetsuya Gatanaga
-
Publication number: 20050158826Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: ApplicationFiled: December 13, 2004Publication date: July 21, 2005Inventors: Tetsuya Gatanaga, Gale Granger
-
Patent number: 6911314Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: GrantFiled: December 29, 2000Date of Patent: June 28, 2005Assignee: The Regents of the University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Publication number: 20050090647Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: ApplicationFiled: October 15, 2004Publication date: April 28, 2005Inventors: Tetsuya Gatanaga, Gale Granger
-
Patent number: 6858402Abstract: The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amount sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.Type: GrantFiled: May 2, 2000Date of Patent: February 22, 2005Assignee: The Regents of the University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Publication number: 20030170776Abstract: The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amount sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.Type: ApplicationFiled: May 2, 2000Publication date: September 11, 2003Inventors: Tetsuya Gatanaga, Gale A. Granger
-
Patent number: 6593456Abstract: The present invention relates to methods of regulating TNF receptor releasing enzyme (TRRE) activity. Composition altering TRRE activity, including a family of proteins and the genes encoding these proteins having TRRE activity, are provided. These proteins, RNA products, or DNA sequences can be administered to individuals suffering from a disease characterized by abnormal TRRE activity. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, an inhibitor of TRRE is administered to the disease site to decrease the local levels of TNF. Methods of isolating other compositons which increase or decrease TRRE activity are also provided.Type: GrantFiled: May 14, 1998Date of Patent: July 15, 2003Assignee: The Regents of the University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Patent number: 6573062Abstract: The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amount sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.Type: GrantFiled: May 2, 2000Date of Patent: June 3, 2003Assignee: The Regents of the University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Patent number: 6569664Abstract: The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amount sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.Type: GrantFiled: November 5, 1997Date of Patent: May 27, 2003Assignee: The Regents of the University of CaliforniaInventors: Tetsuya Gatanaga, Gale A. Granger
-
Publication number: 20020091243Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: ApplicationFiled: December 29, 2000Publication date: July 11, 2002Inventors: Tetsuya Gatanaga, Gale A. Granger